SCHEMBL26745347

SCHEMBL26745347

COC(=O)c1ccc(F)c(OCCCc2c(C)n[nH]c2CO)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 6/20 0.79
▸ ALB P02768 1/20 0.62
▸ AR P10275 1/20 0.43
▸ HSD17B10 Q99714 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ NOTUM Q6P988 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26744380 0.91 TTR (0.65) TTRALBHSD17B10GAASMN1; SMN2
SCHEMBL26740155 0.89 TTR (0.65) TTRALBHSD17B10GAASMN1; SMN2
SCHEMBL15816962 0.88 TTR (1.00) TTRALBARHSD17B10GAA
SCHEMBL17522791 0.85 TTR (0.94) TTRALBARHSD17B10GAA
SCHEMBL25311559 0.84 TTR (0.77) TTRALBARHSD17B10GAA
SCHEMBL26745999 0.83 TTR (0.66) TTRALBARHSD17B10GAA
SCHEMBL21378627 0.82 TTR (0.81) TTRALBARSMN1; SMN2NOTUM
SCHEMBL29433285 0.81 TTR (0.72) TTRALBARHSD17B10GAA
SCHEMBL29433284 0.81 TTR (0.72) TTRALBARHSD17B10GAA
SCHEMBL25310955 0.81 TTR (0.72) TTRALBARHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB TTR 1/4885ALB 6/4885AR 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback